WCLC 2025 - Posters & ePosters-EP.03.05 The Study on the Mechanism of OM-85 in Regulating the Immune Microenvironment in Early-Stage Lung Adenocarcinoma

EP.03.05 The Study on the Mechanism of OM-85 in Regulating the Immune Microenvironment in Early-Stage Lung Adenocarcinoma

Back to course

Pdf Summary

This study investigates the immunomodulatory effects of OM-85 Broncho-Vaxom (BV), a bacterial lysate, on early-stage lung adenocarcinoma (LUAD), which commonly appears as ground-glass nodules with a risk of malignant progression and currently lacks effective pharmacological treatments. Using a genetically engineered mouse model (KrasG12DTgfbr2-/-) that mimics early LUAD pathology, researchers administered OM-85 orally to one cohort and compared tumor burden, survival, and immune responses to a vehicle-treated group.<br /><br />Serial micro-CT scans showed that OM-85 significantly reduced tumor burden and improved survival. Single-cell RNA sequencing revealed expansion of CX3CR1-expressing natural killer (NK) cells within tumor microenvironments, with enhanced cytokine and cytotoxic effector functions. Functional assays demonstrated that OM-85-primed NK cells activated the CX3CR1/IFN-γ signaling axis, effectively suppressing invasiveness of LUAD-derived LKR cells in vitro. Knockdown of CX3CR1 abolished OM-85’s anti-tumor activity, underscoring its key role.<br /><br />Immune profiling using immunohistochemistry, flow cytometry, and ELISA confirmed that OM-85 reshapes the immune milieu by potentiating NK cell-mediated tumor suppression, particularly through IFN-γ-driven inhibition of metastatic priming and stromal remodeling. These findings elucidate the mechanism by which oral OM-85 administration intercepts early LUAD progression via NK cell-centric immunomodulation and support its potential as a novel oral immunotherapeutic strategy to prevent malignant evolution of premalignant lung lesions.

Asset Subtitle

Dawei Yang

Meta Tag

Speaker Dawei Yang

Topic Tumor Biology – Translational Biology

Keywords

OM-85

Broncho-Vaxom

lung adenocarcinoma

ground-glass nodules

immunomodulation

natural killer cells

CX3CR1

IFN-γ signaling

tumor suppression

oral immunotherapy